In several preclinical studies based on lung cancer cell lines and xenografts, EGFR expression was down regulated in response to estrogen and up-regulated in response to ER antagonists (i.e., fulvestrant or tamoxifen) in NSCLC cell lines. The gene discussed is EGFR; the disease is lung carcinoma.